This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Veldhuis, J. D. Articles by Bowers, C. Y. Search for Related Content PubMed PubMed Citation Articles by Veldhuis, J. D. Articles by Bowers, C. Y. Related Collections Neuroendocrinology and Pituitary Female Endocrinology

Tripartite Control of Growth Hormone Secretion in Women during Controlled Estradiol Repletion

Endocrine Research Unit 9 (J.D.V., M.C., D.E., R.P., K.M.), General Clinical Research Center, Mayo Medical and Graduate Schools of Medicine, Mayo Clinic, Rochester, Minnesota 55905; Division of Endocrinology and Metabolism (L.S.F.), Department of Internal Medicine, School of Medicine, University of Virginia, Charlottesville, Virginia 22908; and Endocrine Division, Department of Medicine (C.Y.B.), Tulane University Health Sciences Center, New Orleans, Louisiana 70112

Address all correspondence and requests for reprints to: Johannes D. Veldhuis, Endocrine Research Unit 9, General Clinical Research Center, Mayo Medical and Graduate Schools of Medicine, Mayo Clinic, Rochester, Minnesota 55905. E-mail: veldhuis.johannes{at}mayo.edu.

Context: Studies of how aging attenuates GH secretion are confounded by differences in sex-steroid milieus, abdominal visceral fat mass (AVF), and IGF-I concentrations and limited in interpretability by the use of pharmacological doses of secretagogues.

Hypothesis: In a controlled estrogenic milieu, near-physiological secretagogue drive will unmask distinct influences of age, AVF, and IGF-I on GH secretion.

Location: The study was conducted at an academic medical center.

Subjects: Subjects included 10 healthy pre- (PRE) and 10 postmenopausal (POST) women.

Procedure: In a defined estradiol (E₂) milieu, we compared GH secretion after submaximal stimulation with GH-releasing peptide (GHRP)-2 (ghrelin analog), GHRH, and L-arginine (an inhibitor of somatostatin outflow).

Analysis: We related GH responses to age stratum (dichotomous variable) and AVF and IGF-I concentrations (continuous variables).

Results: In the face of comparable concentrations of E₂, testosterone, and SHBG: 1) age (P < 0.001) and secretagogue type (P < 0.001) independently determined GH secretion; 2) GH responses in POST subjects were only 26–33% of those in PRE (P 0.002) across all secretagogues; 3) POST women lost the PRE order of secretagogue potency (GHRP-2 > GHRH = L-arginine); and 4) in the combined cohorts, higher AVF predicted reduced L-arginine-stimulated GH secretion (R² = 0.46, P = 0.0013), whereas higher IGF-I concentrations forecast increased GHRP-2 and GHRH drive (R² 0.52, P 0.013).

Conclusion: A paradigm of near-physiological secretagogue drive in an E₂-clamped milieu unmasks tripartite deficits in peptide-signaling pathways in healthy POST, compared with PRE, women. Post hoc analyses indicate that both greater visceral adiposity and lower IGF-I concentrations mark this triple regulatory defect.

This article has been cited by other articles:

				G. Fanciulli, A. Delitala, and G. Delitala Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone Hum. Reprod. Update, May 1, 2009; 15(3): 341 - 358. [Abstract] [Full Text] [PDF]